The Ignatian Pedagogy Paradigm and the Global Imperative of Biotechnology by Gunn, Moira A. et al.
Jesuit Higher Education: A Journal
Volume 4 | Number 1 Article 3
January 2015
The Ignatian Pedagogy Paradigm and the Global
Imperative of Biotechnology
Moira A. Gunn
Director, Business of Biotechnology Program & Assistant Professor, School of Management, University of San Francisco,
gunn@usfca.edu
John P. Koeplin S.J.
Associate Professor, School of Management, University of San Francisco, jpkoeplin@usfca.edu
Paul V. Lorton Jr.
Professor, School of Management, University of San Francisco, lorton@usfca.edu
Michael D. Whitty
Adjunct Professor, School of Management, University of San Francisco, mdwhitty@usfca.edu
Follow this and additional works at: https://epublications.regis.edu/jhe
This Praxis is brought to you for free and open access by ePublications at Regis University. It has been accepted for inclusion in Jesuit Higher
Education: A Journal by an authorized administrator of ePublications at Regis University. For more information, please contact
epublications@regis.edu.
Recommended Citation
Gunn, Moira A.; Koeplin, John P. S.J.; Lorton, Paul V. Jr.; and Whitty, Michael D. (2015) "The Ignatian Pedagogy Paradigm and the
Global Imperative of Biotechnology," Jesuit Higher Education: A Journal: Vol. 4 : No. 1 , Article 3.
Available at: https://epublications.regis.edu/jhe/vol4/iss1/3
Gunn et al.: The IPP and the Global Imperative of Biotechnology 
 
 Jesuit Higher Education 4(1): 72-82 (2015)  72 
The Ignatian Pedagogical Paradigm and the Global Imperative of Biotechnology 
Moira A. Gunn 
Director, Business of Biotechnology Program 
Assistant Professor, School of Management 
University of San Francisco 
(gunn@usfca.edu)  
 
John Koeplin, S.J. 
Associate Professor, School of Management 
University of San Francisco 
(jpkoeplin@usfca.edu)  
 
Paul Lorton, Jr. 
Professor, School of Management 
University of San Francisco 
(lorton@usfca.edu)  
 
Michael D. Whitty 
Adjunct Professor, School of Management 
University of San Francisco 
(mdwhitty@usfca.edu)  
Abstract 
The potential of the Ignatian Pedagogical Paradigm (IPP) is realized in the reflective actions of students after 
they leave the Jesuit educational setting and go out into the world. With developments in science and 
technology accelerating, and worldwide dissemination immediate, the imperative to infuse the IPP into areas 
driven by science and technology is clear. It is this imperative which draws us to the global biotechnology 
industry. This paper presents a short overview of the industry, describes how “science-business” differs from 
traditional business, and discusses the process by which the IPP – context, experience, reflection, action and 
evaluation – has been developed in the Business of Biotechnology program at the University of San Francisco 
(USF). The cases developed to exemplify the IPP are “Organized Religion and the Business of 
Biotechnology,” “Humanist Measures for Success in Bio-Business,” and “The Poor and Marginalized.” In 
addition, the Business of Biotechnology program utilizes the Biotechnology Innovation Expertise Model 
(BIEM 2.0), which identifies a recognized complement of the disciplines needed to bring breakthrough 
bioscience to a commercial product. These disciplines are readily present at Jesuit universities, which can, in 
turn, directly support education of value to the global biotechnology industry.  
 
 
Introduction 
There are times in human history when science 
and technology make an unprecedented impact on 
humans and the world in which they live, and, in 
fact, set humanity on a course previously 
unimagined. Obvious examples include the 
printing press, telecommunications and 
computers, and modern medicine. The 
significance of a scientific breakthrough or a new 
technology is typically not understood at its 
outset, and the actual global adoption of a 
technology often took decades. Today, however, 
scientific breakthroughs and new technologies are 
emerging at an unprecedented rate, information 
can be shared globally within seconds, and 
worldwide technology adoption can be 
implemented within months.  
In 2003, the genetic decoding of a severe acute 
respiratory syndrome (SARS) virus from a single 
patient took six days of round-the-clock work by a 
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Canadian team, while a Centers for Disease 
Control (CDC) team, working in parallel in 
Atlanta, added further essential genetic details two 
days later.1 SARS was determined to be different 
from any previously decoded viruses found in 
humans or animals by yet another team at 
University of California San Francisco (UCSF) in 
San Francisco. This feat was accomplished within 
a single weekend.2 The genetic decoding of SARS 
was a global scientific effort, led by the World 
Health Organization (WHO) and involving “115 
national health services, academic institutions, 
technical institutions, and individuals.”3 It was 
only possible through what is now considered 
everyday communications technologies – voice, 
conference calling, the Internet, computers, and 
information sharing, all alongside the will and 
intent of the scientists, scientific expertise, and 
available equipment. 
This moment of global crisis reveals the fabric of 
the world in which our students will live, work 
and contribute. It is a world in which individuals, 
both independently and as participants in larger 
organizations, can expect to be global actors. As a 
result, infusing the Ignatian Pedagogical Paradigm 
(IPP) into educational programs in fields driven by 
science and technology carries great urgency. And 
this imperative draws us to the global 
biotechnology industry.  
This paper presents a short overview of the 
biotechnology industry and describes how 
“science-business” differs from traditional 
business through the lens of higher education. 
This approach highlights how traditional 
implementations of the IPP within business 
education  is insufficient, and discusses the 
process by which the IPP – context, experience, 
reflection, action and evaluation – has been 
developed within the Business of Biotechnology 
program in the School of Management at the 
University of San Francisco (USF). The cases 
developed below demonstrate the IPP as applied 
to the global biotechnology industry. Our 
examples include “Organized Religion and the 
Business of Biotechnology,” “Humanist Measures 
for Success in Bio-Business,” and “The Poor and 
Marginalized.” Of note, the IPP is intentionally 
distinguished from the topic of bioethics, which is 
intrinsic to all biotechnology. Also discussed 
below is how the Biotechnology Innovation 
Expertise Model (BIEM 2.0) is used to 
demonstrate that disciplines readily present at 
Jesuit universities can directly support education 
of value to the global biotechnology industry.  
The Global Biotechnology Industry  
Perhaps the most important aspect when 
considering the global biotechnology industry is 
its dual nature. While its goals are to feed all 
people, heal all disease, and advance ecological 
practices, at its core it is a collection of for-profit 
businesses. As such, it must create a return on 
investment to sustain itself, while much of the 
world is incapable of participating in this 
economic proposition.  
We are now at an historic nexus of science and 
technology. Genes of every living organism can be 
decoded, analyzed, manipulated, inserted and 
extracted. Out of this capability has grown the 
global biotechnology industry, whose imprint on 
humanity has only begun to be felt. In human 
terms, biopharmaceuticals are at the heart of 
precision medicine, offering exact diagnostics and 
treatments based on a patient’s own DNA. On the 
agricultural front, genetically-engineered drought- 
and pest-resistant crops are grown in 27 nations, 
19 of which are designated as developing 
countries. While some crops are transformed into 
alternative fuel, others are foodstuffs and source 
materials (e.g., cotton). In the manufacturing 
sector, bio-engineered industrial enzymes continue 
to replace polluting manufacturing processes, 
supporting the sustainability of the planet.  
In economic terms, the bio-pharmaceutical sector 
sustained 2012 revenues in the $90 billion range, 
while bio-fuels comprised $148 billion of the $5 
trillion global fuel market. The reach of the 
agricultural sector (AgBio) can be viewed as the 
combined output of 420 million acres of 
genetically-engineered crops planted worldwide. 
And the economic sector of industrial enzymes 
reports $3.5 billion in revenues in 2011.4 
The global biotechnology industry creates many 
opportunities in which individuals can bring about 
reflective insight and responsible, creative action, 
which in turn can broaden the industry’s reach to 
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include all humanity. This is the promise of the 
Ignatian Pedagogical Paradigm. 
Is Bio-Business Different? 
From an educational standpoint, it is important to 
ask: Is there a compelling need to address the IPP 
and the global biotechnology industry, separate 
and apart from general business? Significant 
efforts have long infused the IPP into Jesuit 
business education. Is bio-business so different 
from any other business? The response is 
straightforward. First of all, the industry is based 
on the continuous introduction of cutting-edge 
science, with a focus on transforming scientific 
breakthroughs into viable commercial 
technologies. This is called “science-business,” 
and the risks, the potential impact on lives, the 
immediate applicability to all humans and all living 
organisms, and the potential downsides are well-
documented.5 
Unlike other businesses, the science-to-product 
lifecycle also requires an extraordinary 
complement of diverse expertise, and successful 
interaction among the people involved. One 
depiction of the expertise needed is the BIEM 2.0. 
Its initial version was published in the Journal of 
Commercial Biotechnology,6 where it identifies twelve 
essential expertise categories needed by 
bioenterprise, only one of which is science. BIEM 
2.0 enabled the inclusion of bio-medical devices 
along with bio-pharmaceuticals, agricultural 
biotechnology and industrial biotechnology, by 
adding science/technology in addition to simply 
science. BIEM 2.0 is depicted in Figure 1. 
While describing science-oriented business, many 
of the disciplines found in BIEM 2.0 are regularly 
taught at Jesuit institutions of higher learning in 
non-science disciplines: intellectual property, 
venture capital, finance, law, marketing, media, 
ethics and bioethics, information systems, social 
policy and multi-national expertise. They reach 
across the university, while independently playing 
a crucial and dynamic role in the innovative 
science-to-product lifecycle. With the introduction 
of ever-newer science and constantly-changing 
technology, the need for individuals in every 
discipline to incorporate Ignatian values is 
paramount. 
 
Figure 1: Bioenterprise Innovation Expertise Model (BIEM 2.0) 
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Embedding the IPP in the Biotechnology 
Science-to-Product Life Cycle 
The Business of Biotechnology program at the 
University of San Francisco was designed to 
integrate the BIEM 2.0 disciplines of the 
biotechnology science-to-product lifecycle, and to 
engender students across these disciplines to study 
together, as they will work together in industry. It 
is comprised of four lecture courses and a 
complement of one-week global study tours: 
 MBA 6561 Local, National and Global Bio-
Business 
 MBA 6562 The Information of Biotech 
 MBA 6563 Legal, Social & Ethical Implications 
of Biotech 
 MBA 6564 Bioentrepreneurship and the San 
Francisco Bio-cluster (to be scheduled) 
 MBA 6797 Biotechnology Global study tours: 
including London/Oxford/Cambridge, 
Switzerland, Montreal/Quebec City, 
Washington, DC, and Sydney, Australia.   
These courses draw students from degree 
programs across the university, including: MBA, 
JD/MBA, MS/Information Systems, Masters of 
Public Administration, MS/Healthcare 
Informatics, and Professional Science 
Masters/Biotechnology, among others. The multi-
discipline nature of bio-business provides a rich 
opportunity for asking questions of the individual 
in relation to the biotechnology industry in a 
relevant, multi-disciplined setting. 
The Strategy of IPP in Business of 
Biotechnology Courses 
 
Whether designed for individuals or groups, the 
activities and exercises throughout all the courses 
directly embrace Ignatian goals by incorporating 
the five elements that make up the IPP: context, 
experience, reflection, action, and evaluation. In group 
exercises, the Context element requires that group 
members reveal to each other (on a voluntary 
basis) their individual context and framing 
experiences, and similarly, all subsequent phases 
require that dissimilar viewpoints are embraced 
and respected. Three cases are offered as 
exemplars of the IPP. 
Case #1: Organized Religion and the 
Business of Biotechnology 
The orientation of the world’s major religions 
toward biotechnology is set against a multi-
national geographic landscape, wherein products 
must meet each nation’s regulatory environment, 
while both understanding and respecting the 
religious profile of its society. The religions 
studied in the program include Roman 
Catholicism and other Christian religions, Judaism, 
Islam, Hinduism, and Buddhism, and any religion 
or spiritual practice represented by students in the 
class.  
Eliciting comparative religious perspectives with 
respect to biotechnology can be challenging. No 
single viewpoint on the whole of biotechnology is 
offered by any religion; rather, religious positions 
typically relate to selective, specific 
biotechnologies and identify positions on 
particular circumstances of their use. Many 
religions offer multiple interpretations, depending 
upon their internal interpretive structures. Roman 
Catholicism, for example, provides public 
documents. The most recent positions of Roman 
Catholicism vis-à-vis the use of biotechnology can 
be found in the 2008 Vatican Instruction Dignitas 
Personae on certain Bioethical Questions7 and a 
complement of study reports from the Pontifical 
Academy of Sciences regarding agricultural 
biotechnology.8 These documents describe 
relevant underlying science and technology using a 
multi-layered framework for the Church’s or the 
Academy’s position and its rationale.  
By way of example, Dignitas Personae states: “The 
dignity of a person must be recognized in every 
human being from conception to natural death … 
The Church moreover holds that it is ethically 
unacceptable to dissociate procreation from the 
integrally personal context of the conjugal act.”9  
This confirms the Church’s longstanding rejection 
of in vitro fertilization (IVF),10 which is not itself a 
genetic biotechnical procedure. Still, the Dignitas 
Personae Instruction recognizes that today a typical 
precursor to IVF is pre-implantation genetic 
diagnosis. This genetic test analyzes fertilized 
embryos created via IVF external to the human 
body and provides information regarding the 
biological status of each prior to implantation in 
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the prospective mother. Here the Church further 
objects, and the many considerations presented 
include the potential for the “qualitative selection 
and consequent destruction of embryos” and 
“treating the human embryo as mere ‘laboratory 
material’.”11 Of note, Dignitas Personae is the first 
instruction regarding biotechnology since the 1988 
Vatican Instruction Donum Vitae,12 a time span 
representing virtually the entire lifetime of the 
commercial biotechnology industry. At the same 
time, Dignitas Personae is a forward-looking 
document, anticipating a number of projected 
biotechnology developments. 
While students are required to read the primary 
source material of Dignitas Personae, multi-religion 
insights are more often found in the peer-
reviewed literature and select textbooks. 
Continuing on the theme of IVF and pre-
implantation genetic diagnosis, both individual 
and multi-religion insights are available. Ari 
Zivotofsky and Alan Jotokowitz published “A 
Jewish Response to the Vatican’s New Bioethical 
Guidelines,”13 and in “Assisted Reproductive 
Technologies and World Religions: Implications 
for Couples Therapy,”14 Jennifer Connor, et al. 
discuss points of agreement and disagreement 
across Judaism, Christianity, and Islam, providing 
independent analyses of Judaism, Roman 
Catholicism, Protestant Christianity, and Islam, as 
well. The later paper is oriented to advising 
couples and considers the implications of 
generational familial beliefs, cultural perceptions 
and legal impacts in some geographic areas. In 
support of projects during the course, students 
seek out sources in the literature relevant to their 
focus area. 
In a very few topic areas are textbooks available 
and sufficiently up to date given the emergence 
and adoption of biotechnology. One current 
example in the agricultural biotechnology space is 
Acceptable Genes? Religious Traditions and Genetically 
Modified Foods,15 published in 2009 and edited by 
Conrad Brunk and Harold Coward. It provides 
insights from a series of authors regarding 
Judaism, Christianity, Islam, Buddhism, Hinduism 
and indigenous peoples. This is used in contrast to 
the Pontifical Academy reports, 16 which are 
supportive of genetically-modified agriculture in 
the interests of feeding humanity. This book 
focuses instead on religions wherein dietary laws 
play a strict role.  
The challenge is quite simply that biotechnology – 
as with all technologies – continues to evolve, 
while organized religions must respond with due 
diligence and consideration. In fact, prior 
positions may be re-evaluated and refined, new 
positions must anticipate the response to future 
technologies. Case in point, early stem cell 
therapies derived source materials from embryonic 
stem cells, which could not be approved by the 
Roman Catholic Church. Yet, in Dignitas Personae, 
stem cell therapies were projected to be acceptable 
if adult stem cells could be used. While sourcing 
from adult stem cells has not materialized 
substantively as yet in the industry, there is 
significant commercial research and development 
underway, and arguably, stating the potential for 
acceptability can affect the course of human 
innovation. Other considerations in Dignitas 
Personae include assessing risk to individuals with 
each new technology and examining the potential 
for passing genetic modifications on to progeny.  
In-class discussions range from identifying the 
religious profiles of various countries, to the 
national acceptance/rejection of genetically-
engineered crops/food, to considerations about 
the individuals with respect to religious and 
spiritual practice, to students’ own experience, 
actions and reactions.  
One specific example used is Living Cell 
Technologies, a New Zealand/Australian firm 
which is working on placing insulin-producing 
cells from pigs inside a nano-material sack 
embedded beneath the skin. While these sacks 
have successfully been shown in trials to be 
effective in producing insulin for sustained 
periods, it is important to consider that for those 
of the Muslim and Jewish faiths, consumption of 
pork is forbidden. Would this technology be 
considered consumption? Would it be acceptable 
if certain constraints could be met? How might 
one address this? Other discussion points with 
religious implications include: in vitro fertilization, 
pre-implantation embryonic testing, embryonic 
stem cell research, therapeutic cloning and animal 
cloning. 
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Individual assignments require that student select 
a topic or product relevant to the biotechnology 
industry. This could reflect a company, a 
regulatory body, a nation, a law, an advocacy 
group, etc. Students must then investigate their 
choice with respect to a candidate organized 
religion.  
As an individual exercise, the following aspects are 
included:  
 Context: The individual’s own history vis-à-vis 
organized religion, his/her current religious 
orientation/affiliation (if any), and history vis-
à-vis the candidate religion.  
 Experience: The student is encouraged to relate 
his/her own religious life experience to the 
issue at hand. The student then performs a 
differential analysis, if the candidate religion is 
different from his/her own religion of origin.  
 Reflection: As a part of the experiential process, 
the student is asked to reveal elements which 
are bothersome, disingenuous, problematic, 
incomprehensible, frustrating, etc. regarding 
the issue. Students are encouraged to interact 
with those of relevant faiths – both inside and 
outside of their class, if a religion other than 
their religion of origin or personal choice was 
selected.  
 Action: Students are asked to propose potential 
actions and solutions. Frequently, these relate 
to the discipline of their degree program; thus, 
students are encouraged to interact with those 
from other disciplines to expand perspectives, 
enlarge options, review viability, etc.  
 Evaluation: Students are asked to share their 
experience of understanding the issue and their 
attempt to create workable solutions. This 
includes understanding the basis for false 
starts, what could and could not be resolved 
with the actions proposed, and what remains to 
be addressed. 
As a group exercise, adjustments are made to take 
advantage of a mixed-discipline, potentially mixed-
religion group with the capability of creating far 
more diverse solutions. They quickly dispatch 
unworkable solutions, given insights from 
particular disciplines. Group exercises give the 
students experience in respecting all involved. 
 
Case #2: Humanist Measures for Success in 
Bio-Business 
 
Traditional business measures fall short when 
applied to bio-business, especially when the 
successful use of biotechnology products can save 
human lives and/or reduce human suffering.  
One example presented to Business of 
Biotechnology students is Genomic Health, Inc., a 
profitable, publicly-traded genetics diagnostics 
firm (GHDX [NASDAQ]) which specializes in 
improved diagnostics for breast, colon and 
prostate cancers. In the case of breast cancer 
patients where chemotherapy is the recommended 
standard of care, only four in 100 women who 
receive chemotherapy actually benefit from the 
treatment. Most patients and their doctors choose 
the chemotherapeutic option in the hope that they 
will be one of the four per cent for whom it will 
work.  
Since its introduction, Genomic Health’s 
Oncotype DX test has provided further analysis 
of tumors’ genetic composition. Is the cancer 
aggressive? Will it be responsive to chemotherapy, 
and to which particular chemotherapy drugs?  
In a 2012 Canadian decision-impact study, 
physicians changed their treatment 
recommendations 30% of the time given the 
result of the Oncotype DX test. Within those 
decision changes, 20% of the patients were 
advised to omit chemotherapy, while 10% were 
advised to add particular chemotherapy when test 
results predicted the treatment would be 
beneficial. Since the test became available, the use 
of chemotherapy in the United States for these 
specific conditions has steadily declined, which 
turn reduces the suffering caused by uninformed 
treatments.17  
At the same time, Genomic Health has come 
under pressure from financial industry analysts to 
reduce the 20% it feeds back into its budget for 
further research and development (R&D). A more 
typical R&D re-investment range might be 5%-
9%. Measuring “suffering saved” enables 
economics to be balanced with service to others, 
while the company remains financially sound. 
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Class discussion revolves around attempting to 
identify other conditions for success, such as 
alleviating human suffering, reducing impact on 
families, arguing for long-term goals vs. short-
term return, quantifying value in non-economic 
terms, etc.  
Individual assignments require that students select 
a non-economic, atypical measure for success, 
then select a candidate company/product to 
evaluate. These individual exercises include the 
following aspects:  
 Context: The individual’s own history with 
respect to this measure and the candidate 
company/product.  
 Experience: Students are encouraged to relate in 
their own words why that measure is important 
and its impact on people and society external 
to his experience.  
 Reflection: As a part of the experiential process, 
students are asked to describe the impact on 
individuals and society if this measure was 
achieved.  
 Action: Students are asked to propose potential 
actions and solutions. These solutions may 
include changes to basic business models, laws, 
social policy, regulations, etc.  
 Evaluation: Students are asked to express their 
experience with this exercise and how they 
personally felt with the realization that this 
could be an actual measure of success.  
As a group exercise, the experience matches that 
of Case #1. 
Case #3: The Poor and Marginalized 
 
In 2001/2002, Gilead Sciences, Inc. (GILD 
[NASDAQ]) received approval for its HIV 
medication Viread in the United States and 
Europe. Taken once per day orally with a meal, 
Viread was a breakthrough for patients, as 
previous medications required multiple pills at 
varying intervals. With patent protection through 
2017/2018, this period is typically used in the 
pharmaceutical industry to recover investment and 
establish full profitability. But in 2003, Gilead put 
into place an access program enabling all African 
countries and 15 other nations identified by the 
United Nations as “least-developed” to obtain 
Viread at non-profit cost. Of note, it was 
implemented well in advance of recovering the 
investment made to develop and bring Viread to 
market, and it was presented as a separate 
calculation from that endeavor. Two years later, 
Gilead further reduced the cost of Viread by 37%, 
to approximately $0.82/day at a time when the  
full retail price of the drug was approaching 
$20.00/day.18  
Today, 4.7 million people in low- and middle-
income countries receive Gilead HIV therapies at 
reduced pricing through a variety of innovative 
economic programs, including voluntary generic 
licensing and local business partnering.19 
Students are asked to consider the premise: If a 
technology exists that relieves a disease, is it 
inhumane to deny it to any human?  
Individual assignments require that students think 
inventively about addressing the totality of human 
needs, while creating and nurturing economically-
viable business propositions. They are asked to 
design programs which serve all humanity from 
the outset, and they are encouraged to invent new 
business groundrules. As an individual exercise, 
the following aspects are included:  
 Context: The student is asked to pick a product 
– approved or not yet approved, real or 
fictitious. The individual is asked to reveal 
his/her own history with respect to the 
treatment and/or condition.  
 Experience: The student is encouraged to 
explore all the people globally who require the 
treatment, and their actual condition: socio-
economic, environmental, etc. The student is 
asked to reveal what groups or situations s/he 
found surprising in this quest.  
 Reflection: As a part of the experiential process, 
the student is asked to reveal which people 
affected him/her the most, and what s/he 
learned that s/he did not know, and needed to 
know, or s/he would not have a workable 
action.  
 Action: Students are asked to propose potential 
actions and solutions. These solutions may 
include changes to basic business models, laws, 
social policy, regulations, etc. There may be 
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multiple solutions, or only solutions for some 
subgroups.  
 Evaluation: Students are asked to express their 
experience with this exercise, and to evaluate 
what solutions were successful and what 
problems remain to be addressed.  
As a group exercise, the experience matches that 
of Cases #1 and #2. 
Bioethics, the IPP, and Curriculum Values 
It should be stated that bioethics is a separate and 
important field, with a larger purview than today’s 
biotechnology industry. Furthermore, ethical 
challenges are typically not the driver of new 
action. Through the IPP, an individual can have 
the vision to improve on an ethical situation, 
producing a greater human benefit. Aspects of 
bioethics relevant to the biotechnology industry 
are included throughout the Business of 
Biotechnology curriculum on a specific basis, and 
should not to be confused with the incorporation 
of the IPP into assignments, the personal journey 
IPP seeks to engender, or the habit of creative 
action IPP supports. While bioethical issues can 
sometimes overlap with IPP-embedded exercises, 
they are not one and the same. Margaret McLean, 
the Director of Biotechnology and Health Care 
Ethics at the Markkula Center for Applied Ethics 
at Santa Clara University refers to this area of 
bioethics as “biotech ethics” and provides a more 
biotechnology industry-relevant framework in 
what she terms “Reasoning into Biotech 
Practice.”20 It is essentially this “biotech ethics” 
framework which is largely utilized throughout the 
USF curriculum. 
Another aspect which relates to this topic is the 
question of values and IPP practice measurement 
among adult students. Graduate student practices 
of reflection over time within a degree program 
were measured, presented and discussed by Coiro, 
et al.,21 with focus on the reflection portion of the 
IPP and the adult student. This is particularly 
germane to students in the Business of 
Biotechnology courses, as they are all post-
graduate. Complementary research has begun and 
is in its formative stages in the Business of 
Biotechnology Program, measuring student 
perception of Jesuit values as expressed in USF’s 
mission and values statement and its reflection in 
individual course content. In some cases, this has 
been measured on exit, while in others, it is being 
measured on a differential entry-and-exit basis. 
This is an extension of the GLAS project, the 
Gunn-Lorton Attitudinal Survey, which also 
includes undergraduate testing. This approach of 
“testing the course” is at its center of focus,22 and 
it proves to be a complex, yet important, question. 
U.S. Jesuit Universities and Bioenterprise-
Relevant Education 
Taken together, the capability of the 28 U.S. Jesuit 
universities to address bioenterprise-relevant 
education is undeniable. They sustain three 
medical schools, and six PhD programs in 
Biology. Fourteen of these universities host law 
schools, another fourteen offer joint JD/MBA 
degrees, six offer a Masters in Biology, and all 28 
U.S. Jesuit universities have Biology departments. 
All but one of these universities have a business 
school. 
Specific bioenterprise-relevant education varies 
with other degree programs in place. In the area of 
the biopharmaceuticals, these courses may 
embedded within healthcare management 
programs. St. Joseph University offers a 
Pharmaceutical and Healthcare Marketing MBA 
for Executives, while both Gonzaga University 
and Loyola University Chicago offer MBAs in 
Healthcare Management. Marquette University 
offers a Masters in Healthcare Technology 
Management. 
Health informatics is represented by such 
programs as St. Joseph’s Online Masters in Health 
Administration with an Informatics Specialization, 
while Le Moyne College offers a certificate for 
working professionals in Health Information 
Systems. The University of San Francisco has 
commenced a Masters in Health Informatics in 
online, onsite and hybrid forms originating from 
the School of Nursing and Health Professions.   
Jesuit law schools are participating in the 
biotechnology field with Santa Clara University’s 
focus on biotechnology law. SCU offers such 
courses as Assisted Reproduction, Cloning, and 
Genetic Engineering, as well as a Biotechnology 
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Law Seminar. SCU’s offering is complemented by 
the Markkula Center for Applied Ethics’ focus on 
bioethics. St. Louis University School of Law 
offers the course Biotechnology Law and Policy, 
while USF’s School of Law offers courses on 
Science and the Law, and Biotechnology Law. 
In addition to its Business of Biotechnology 
program described earlier, USF commenced a 
Professional Science Masters in Biotechnology 
degree program in its College of Arts & Sciences 
in 2012, collaborating with the Business of 
Biotechnology program to achieve the required 
topical business credits. Creighton University had 
less success with its Professional Science Masters 
(PSM) in Bioscience Management. This is due in 
some part to the fact that Omaha is a challenging 
geographic area in which to recruit the PSM-
required biotechnology internships from local bio-
businesses. Still, Creighton has continued with its 
undergraduate Bioscience Management track in 
the Marketing and Management bachelors 
program. 
Since 2008, USF has offered a Masters in 
Information Systems with a concentration in 
Biotechnology, which incorporated Business of 
Biotechnology courses. In engineering, Marquette 
University has a full roster of degrees in the field 
of Biomedical Engineering – ranging from 
bachelors to PhD. Fordham University offers a 
certificate in biomedical informatics.  
This overview of Jesuit education in the field of 
bioentrepreneurship is not meant to be 
exhaustive, but rather to demonstrate that every 
Jesuit university has the capability to support 
many aspects of bio-business, as demonstrated by 
the BIEM 2.0 model. Such programs can be 
developed by a roster of interested faculty across 
schools in the respective universities and can 
incorporate efforts already underway to develop 
flexible, cohesive, university-wide bioenterprise-
focused programs. Each course and each program 
can incorporate the IPP successfully in every 
instance. Also, the success of engendering non-
science professional graduate students with 
significantly increased comfort levels toward the 
biotechnology industry was measured on 
successive study tours to global bio-clusters.23 It is 
indeed possible to develop an appreciation for and 
understanding of the global biotechnology 
industry for those with no formal science training 
in their undergraduate and graduate university 
experience.  
It should be noted that a complement of non-
Jesuit higher education bioentrepreneurship 
courses and programs have emerged globally in 
recent years.  Dr. Lynn Johnson Langer, a 
program director at the Johns Hopkins 
University’s Center for Biotechnology Education, 
cites a selected list of 26 such bioentrepreneurship 
programs in “Building a Curriculum for 
Bioentrepreneurs”, which was published in Nature 
Biotechnology Bioentrepreneur.24 Of the 26 programs 
identified, 19 are located in the United States, 
while only one is at a Jesuit university (USF). 
Bioentrepreneurship programs are just now taking 
shape for good reason – the U.S. biotechnology 
industry has matured and its employment needs 
are now on the rise. In this case, employment 
potential is driving development of academic 
programs. 
Conclusion: The IPP and the Global 
Imperative of Biotechnology 
While biotechnology naturally attracts those who 
wish to serve others, the industry is problematic as 
a profitable business proposition. Biotechnology 
products require astonishing investments over 
many years, and efforts are continually fraught 
with the looming specter of failure. At the end of 
this period, there are only a relatively few years to 
recover the investment and generate profits. The 
2014 report from the Tufts Center for the Study 
of Drug Development estimates the cost to 
develop a successful new drug to be $2.6 Billion.25 
Of the some 1,400 drug compounds the report 
examined, only 7% were approved, 80% were 
discontinued, and 13% were still actively being 
pursued. If all the currently active drug candidates 
succeed, it still means that 4 out of 5 fail. And 
successful drugs can take 11-15 years to reach 
approval.26  
But the rewards of working in the biotechnology 
industry refuse to be measured by such standards. 
With success, biotechnology can save lives, reduce 
suffering, change the world for the better, and 
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lead us all to know ourselves in ways we never 
previously imagined. 
The importance of a Jesuit education is that it 
goes beyond business fundamentals and 
hypothetical discussions of the ethical issues 
involved – it teaches the individual about the 
importance of context. It is a call to reflect, a 
requirement to experience, a freedom to create 
innovative action, and a habit of evaluation. This 
paper seeks to document both the importance of 
instilling Ignatian values in the burgeoning 
biotechnology sector, as well as the ability of Jesuit 
universities to educate both scientific and non-
scientific biotechnology industry professionals.  
But the premise is greater than that. The role for 
Jesuit education in supporting the biotechnology 
industry is a higher calling: To educate those who 
will participate in bioenterprise with an 
appreciation for the world, a respect for life – 
both individually and collectively, a sense of 
relevancy to the moment, a penchant for realistic 
assessment, an inclusionary vision of religion and 
spirituality, a larger definition of values, a sense of 
participating in a great human quest for good, an 
increased sense of self in a changing world, a 
sensibility to include the poor and marginalized in 
unprecedented ways, a perception that new rules 
can be made and new systems built, and a license 
to act in a larger context. 
This is a promise on which Jesuit education can 
deliver.  
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